ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human tests begin for potential Alpha-1 treatment
Disease control CompletedThis early-stage study tested the safety and how the body processes WVE-006, a potential new treatment for Alpha-1 antitrypsin deficiency. It involved 47 healthy volunteers who received either the drug or a placebo. The goal was to find safe dose levels to use in future studies w…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Augmented reality eyewear aims to help patients stick to crucial breathing therapy
Symptom relief CompletedThis study tested if using augmented reality (like special glasses or screens) could help adults with a genetic lung condition called Alpha-1 stick to their prescribed breathing exercises and daily walking. Fifty participants did breathing exercises twice daily and walked at leas…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: University of Parma • Aim: Symptom relief
Last updated Mar 23, 2026 15:19 UTC